Navigation Links
New myeloma drug shows promise in early testing
Date:6/7/2010

ANN ARBOR, Mich. A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer.

A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism. The early stage trial combined elotuzumab with bortezomib, or Velcade, one of the novel chemotherapies approved to treat multiple myeloma, a cancer that arises in the plasma cells.

"Elotuzumab was found to work in synergy with bortezomib in a pre-clinical model, which served as the basis for this clinic trial. The regimen was well-tolerated, and many patients stayed on it for a long time," says Andrzej Jakubowiak, M.D., Ph.D., director of the Multiple Myeloma Program at the University of Michigan Comprehensive Cancer Center. Jakubowiak presented results of the study at the American Society of Clinical Oncology annual meeting.

The study looked at 28 patients with multiple myeloma that had relapsed or become unresponsive to treatment. Overall, 48 percent responded to the elotuzumab and bortezomib combination and patients' cancer progressed after an average 9.45 months. These numbers are better than in previous studies of patients with less advanced disease treated with bortezomib alone in which 38 percent responded to the treatment and cancer progressed after an average of 6.22 months.

"The study was not designed to evaluate statistical superiority of the combination of elotuzumab and Velcade, but it does appear to support our preclinical evidence that these two drugs work together," Jakubowiak says.

The researchers will next consider a study to compare the combination of elotuzumab and bortezomib against standard therapy to see if the combination achieves better results.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Page: 1

Related medicine news :

1. Drug shows positive responses, low side-effects in multiple myeloma
2. Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
3. Multiple myeloma patients experience high response rate with new 3-drug combination
4. Experimental targeted therapy shows early promise against medulloblastomas
5. Targeted Therapy Shows Promise Against Deadly Brain Cancer
6. Selenium shows no benefit in prevention of lung cancer
7. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
8. Spending time in nature makes people feel more alive, study shows
9. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
10. Prostate Cancer Vaccine Shows Few Side Effects
11. Brief Exercise Reduces Impact of Stress on Cell Aging, UCSF Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... in healthcare communications and education, announced today its ... (AMP), the nation’s only medical conference designed for ... ischemia and lower limb amputation due to vascular ... family of innovative, evidence-based publications and CME activities ...
(Date:3/5/2015)... Califia Farms , the fastest-growing natural ... coffee drinks category[1], today unveils its new Concentrated Cold ... Calif. Concentrated Cold Brew (CCB) is the centerpiece ... the next wave of the coffee-taste evolution by giving ... their own baristas. , Califia Farms CCB has ...
(Date:3/5/2015)... March 05, 2015 Taking center ... Fort Worth, Texas April 9-11th is IDRevolution hosted ... providing personalized nutrition. IDLife offers a variety ... This customized approach to vitamin supplementation is ... with a free HIPAA compliant online assessment and ...
(Date:3/5/2015)... San Diego, CA (PRWEB) March 05, 2015 ... only the purest and most essential ingredients, the robust ... risk of allergic reactions. PASCHA Chocolate is free ... rice and sesame. Experience PASCHA's offering March 6th- 8th ... Smile! Chocolate Spread. PASCHA Chocolate has broken new ...
(Date:3/5/2015)... 2015 INTEGRATED Healthcare Strategies, a ... participate in its 2015 Children’s Hospitals Executive Compensation ... director-level positions, and the survey results are exclusive ... featured data on 60 executive and director level ... and 7 subsidiary children’s hospitals. Additionally, it provided ...
Breaking Medicine News(10 mins):Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:IDLife Partners John C. Maxwell and Troy Aikman speaking at IDRevolution in Fort Worth, TX April 9th-11th, 2015 2Health News:PASCHA Allergen Free Organic Chocolate to Appear at Natural Products Expo West March 6-8, 2015 2Health News:Participation Is Now Open For INTEGRATED Healthcare Strategies 2015 Children’s Hospitals Executive Compensation Survey 2
... commentary on the concerns of successive Australian governments, a ... the health of aborigines lags an appalling one century ... Torres Strait Islander people have significantly worse outcomes than ... ,In New Zealand, while inequality exists between Maori ...
... to improve patient care. In a recent report the use of ... US alone who succumb to sudden infant death syndrome each year. ... of Texas has come up with a new solution for sudden ... along with his friends developed a device that can warn a ...
... is causing confusion among scientists, //is the mystery of ... decipher the reason for this. Normal healthy adult bees abandon the ... ago it was seen that a mass exodus would leave the ... in the new phenomenon it is seen that new bees ...
... height of their football career is unparallel. This glamour and ... retires, and very soon replaced with depression. This is highlighted ... Health System. ,The chronic pain of the injuries ... often come to fore once they retire. This coupled with ...
... that antioxidant supplements interfere with the therapeutic effects ... //review of the use of antioxidants during chemotherapy. ... tumor response, and the patient’s ability to tolerate ... whose oncologists discourage the use of antioxidant supplements ...
... unusual scourge among the Mauritanian nomads - the force-feeding of ... ideal for brides-to-be. ,Mothers cross sticks around the ... girls cry out in pain. ,That is one ... of couscous for days on end until they developed wings ...
Cached Medicine News:Health News:Aborigines Century Behind the Health of Colonizers, WHO Report 2Health News:RFID Use can Avoid Sudden Infant Death Syndrome 2Health News:Vanishing Honey Bees 2Health News:Ex Pro-football Players Saddled With Depression After Retirement 2Health News:Antioxidants May Aid Chemotherapy Patients 2Health News:Force-feeding a Scourge Among Mauritanian Nomads 2Health News:Force-feeding a Scourge Among Mauritanian Nomads 3
(Date:3/5/2015)... , March 5, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... the development and commercialization of targeted antiviral therapies, announced ... Annual ROTH Conference, to be held March 8-11, ... James Sapirstein , Chief Executive Officer, ... his live presentation and will be available to participate ...
(Date:3/5/2015)... Calif. , March 5, 2015  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, announced today that ... the nation,s top rehabilitation hospitals for spinal cord injury ... 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in ... spinal cord injury (SCI). The Phase ...
(Date:3/5/2015)... YORK and VANCOUVER, British Columbia ... (CSE: BUX FSE: 20B OTCQB: BMKDF) -- The ultimate ... an assay that is capable of detecting tumors before ... forty years, the development of such an assay has ... in academia and industry. Although many breakthrough diagnostics have ...
Breaking Medicine Technology:ContraVir to Present at 27th Annual ROTH Conference 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4New Cancer Diagnostic Primed to Change the Industry 2New Cancer Diagnostic Primed to Change the Industry 3New Cancer Diagnostic Primed to Change the Industry 4
... of Rosetta Genomics, microRNA-based,Test, miRview(TM) Squamous, Which Differentiates Squamous From non Squamous ... Diagnostic Methods, A Test Based on the miRview(TM) Technology First Approved for ... ... Earlier This Year, Rosetta Genomics is Expecting to Launch ...
... from the,French Medicine Agency (AFSSAPS) the authorization to ... PL37, its lead compound for oral,treatment of neuropathic ... pain condition, with an estimated,prevalence in the world,s ... most,recent surveys, with many causes such as shingles, ...
Cached Medicine Technology:Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2
The BacT/Alert 3D Select Link is a state of the art, automated microbial detection system that integrates blood, sterile body fluid and mycobacteria culturing. This system is useful when patient data...
The Vitek 2 - XL is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat ...
IDS Rapid Yeast Plus, a microbial identification system....
IDS Rapid One, a microbial identification system....
Medicine Products: